drugset / Trial / NCT05217303
HL-085 in NRAS-mutated Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This was an open-label, single-arm, multi-center phase II clinical study, aimed at investigating the efficacy and safety of HL-085 capsule in the treatment of advanced melanoma patients with NRAS mutation.
Timeline
- Start
- 2020-11-02
- Primary completion
- 2023-02-19
- Completion
- 2023-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tunlametinib | Small molecule | 12 mg | Oral |